Table 1 Baseline characteristics of patients with pancreatic ductal adenocarcinoma (n = 138)
From: Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
Factors | n (%) | Median (IQR) | Missing |
|---|---|---|---|
Age at diagnosis (years) | 68.5 (63.0–73.0) | ||
Gender (female) | 73 (52.9) | ||
Size of primary tumor (cm) | 3.0 (2.5–4.0) | ||
T stage | |||
- T1 | 19 (13.8) | ||
- T2 | 92 (66.7) | ||
- T3 | 26 (18.8) | ||
- T4 | 1 (0.7) | ||
N stage | 0.7% | ||
- N0 | 34 (26.4) | ||
- N1 | 52 (37.7) | ||
- N2 | 51 (37.0) | ||
AJCC stage, eighth edition | 0.7% | ||
- IA | 6 (4.3) | ||
- IB | 20 (14.5) | ||
- IIA | 7 (5.1) | ||
- IIB | 52 (37.7) | ||
- III | 52 (37.7) | ||
Tumor differentiation | 0.7% | ||
- Well | 7 (5.1) | ||
- Moderate | 48 (34.8) | ||
- Poor | 78 (56.5) | ||
- Anaplastic | 4 (2.9) | ||
Positive resection margin (≥R1) | 53 (38.4) | ||
Adjuvant chemotherapy | 111 (80.4) | 3.6% | |